Neuro- Dynamic Sciences

ND SCIENCES IS A LIFE SCIENCES ORGANIZATION FOCUSED ON RESEARCHING AND DEVELOPING SITE SPECIFIC DELIVERY METHODS FOR A RANGE OF CHRONIC DISEASES

OUR RESEARCH CLINICAL STUDIES AND PATENTS

MINIMALLY INVASIVE DRUG/AGENT DELIVERY TECHNOLOGIES

VASCULATURE DAMAGE CORRELATES TO ONSET OF CHRONIC DISEASES

NOVEL SOLUTIONS FOR CRITICAL UNMET VASCULAR DISEASE NEEDS

PRE-ORDER

MORAL HAZARD

A True Story by Henry Broeska

In 2014, a small Canadian non-profit research organization is following MS patients who enroll in a clinical trial involving a first-of-its-kind technique that delivers the patients’ own stem cells directly to targeted cranial veins. Nobody expects the study participants to see the dramatically improved health that follows. Social media and small town newspapers across the US and Canada are reporting on seemingly miraculous patient recoveries. Could it be that the cause of MS is vascular dysfunction? If true, that makes 40 years of drug research virtually meaningless. Billions of dollars of MS drugs on the shelves and in the research pipelines would be made worthless. To what lengths would the giant drug companies go to stop this potentially new discovery from moving forward with Phase II trials? As it happens, the drug companies have indeed taken notice. Clandestine operatives reach into their bag of dirty tricks. Within months, a coordinated smear campaign involving corrupt Canadian and Australian reporters hits the mark. Daily headlines call the clinical trial a "scam," and label the researchers as "fraudsters." The research is suspended under unrelenting personal attacks by the media. A physician suffers the suspension of her medical license after a kangaroo court show trial by her Canadian medical board. Meanwhile, following the strong evidence, a newly re-assembled team of medical investigators in California work toward fresh clinical trials. To build a bulwark against another attack, the group forms alliances with the US FDA, the FBI, and a major university. Thinking they are insulated against renewed assault, they begin to publish their data and file for patents. But is it a fool's errand? Despite protections from key agencies, tensions suddenly increase and the stakes get higher. This time, personal threats are made. How will this end?…This true story, worthy of a movie treatment, is a bellwether for all independent medical researchers on the verge of great discovery…

Report abuse